Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multicenter, Randomized, Open Label Two Arm Study Evaluating the Effect of Crizanlizumab + Standard of Care and Standard of Care Alone on Renal Function in Sickle Cell Disease Patients ≥ 16 Years With Chronic Kidney Disease Due to Sickle Cell Nephropathy (STEADFAST)

Next Previous
X
Search
Trial Profile

A Phase II, Multicenter, Randomized, Open Label Two Arm Study Evaluating the Effect of Crizanlizumab + Standard of Care and Standard of Care Alone on Renal Function in Sickle Cell Disease Patients ≥ 16 Years With Chronic Kidney Disease Due to Sickle Cell Nephropathy (STEADFAST)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crizanlizumab (Primary) ; ACE inhibitors; Angiotensin receptor antagonists; Hydroxycarbamide
  • Indications Sickle cell anaemia
  • Focus Pharmacodynamics
  • Acronyms STEADFAST
  • Sponsors Novartis; Novartis Pharmaceuticals

    • Most Recent Events

    • 08 Mar 2024 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
    • 22 May 2023 Status changed from active, no longer recruiting to completed.
    • 18 May 2023 This trial has been completed in Ireland (Date of the global end of the trial: 20- Mar 2023).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top